| Revenue growth | 19.62% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin at 25.5% (calc); PAT margin at 9.1% (calc). |
| Demand visibility | Strong; 3.19 million tests performed in Q1 alone. |
| Management confidence | High; citing strategic refinement and rapid network scaling. |
Growth
Q1 FY27 revenue reached ₹82.26 Cr (up 19.62% YoY) and PAT hit ₹7.50 Cr (up 29.51% YoY).
Outlook
Targeting 1,000+ franchises by FY27; launching 2 PET-CT centres and Genome Lab; expanding pan-India network via CMC model.
Risks
Realignment through pharmacy business exit; competitive landscape in Tier 2/3 markets; high reliance on North India.
Investor Presentation filed with NSE, NSE: CHANDAN. Summary written with AI assistance from the document.
Chandan Healthcare Ltd: key numbers
- Share price
- ₹241.05
- Market cap
- ₹619.5 Cr
- Revenue (annual)
- ₹276.4 Cr
- Net profit (annual)
- ₹28.55 Cr
- P/E (TTM)
- 21.7×Sector 53.1×
- Promoter holding
- 49.61%+0.06% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandan Healthcare Ltd
All →Chandan Healthcare Capacity Expansion
Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
- diagnostic franchise collection centres
- 500 franchise centres
Chandan Healthcare Results Correction
Chandan Healthcare clarified to NSE it has one reportable segment, explaining the omission of segment-wise details in its Q4 FY27 financial results.
Chandan Healthcare Capital Structure Change
Chandan Healthcare Limited has allotted 5,99,998 equity shares upon conversion of fully convertible warrants, aggregating to ₹14.04 Crore.
- Value
- ₹14.04 Cr
Chandan Healthcare Board Meeting Outcome
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Annual General Meeting
Chandan Healthcare Limited announced the EGM voting results held on 29 August 2026. Shareholders approved the disinvestment of its entire shareholding in Chandan Pharmacy Limited.
Chandan Healthcare Annual General Meeting
Chandan Healthcare Limited held an EGM to approve the disinvestment of its entire stake in subsidiary Chandan Pharmacy Limited for approximately ₹16.77 Crore. This strategic divestment focuses resources on core diagnostics.
- Value
- ₹16.77 Cr